The strategy—sometimes called “vibe coding” —mirrors how some of the biggest players in Silicon Valley write code these days.
A critical vulnerability in the popular Node.js sandboxing library vm2 allows escaping the sandbox and executing arbitrary ...
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Wedbush downgrades Replimune Group (REPL)
Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...
In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...
Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
April 10 (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Replimune's (REPL.O), opens new tab drug for advanced skin cancer, citing insufficient data from studies, ...
FDA delivered a second complete response letter rejecting Replimune’s RP1 advanced melanoma treatment The therapy was under review for use with Bristol Myers Squibb’s (BMY) Opdivo immunotherapy ...
FDA issued a second complete response letter denying approval for Replimune’s RP1 melanoma immunotherapy The treatment was under review for use with Bristol Myers Squibb’s (BMY) Opdivo Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results